Dalacin, vaginal suppositories 100 mg 3 pcs

Dalacin is an antibiotic of lincosamide group for topical use.

The mechanism of action is associated with inhibition of protein synthesis in the microbial cell through interaction with the 50S-subunit of ribosomes.

It has bacteriostatic action; in higher concentrations against some microorganisms it is bactericidal.

The drug is active against microorganisms causing bacterial vaginosis: Gardnerella vaginalis, Mobiluncus spp., Mycoplasma hominis, Peptostreptococcus spp., Bacteroides spp.

Indications

Bacterial vaginosis.

Active ingredient

Composition

1 suppository contains clindamycin (in the form of phosphate) 100 mg;

accessory substances:

solid fat (Witepsol H-32, a mixture of triglycerides, diglycerides and monoglycerides).

How to take, the dosage

A single dose (1 suppository) is placed in the vagina before bedtime for 3 consecutive days.

The suppositories can be inserted without and with an applicator.

After each use, the applicator should be washed with warm water and soap and dried well.

Interaction

An antagonistic interaction between clindamycin and erythromycin has been demonstrated under in vitro conditions.

It has been found that when used systemically, clindamycin impairs neuromuscular transmission; therefore, the effect of peripheral myorelaxants may be enhanced. This fact should be taken into account when prescribing the latter with Dalacin.

No interactions have been observed in pharmacodynamic, pharmacokinetic or clinical studies of these dosage forms.

Special Instructions

The following possible causative agents of vulvovaginitis should be excluded by specific laboratory methods before prescribing the drug: Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus.

Intravaginal use of Dalacin may lead to increased growth of microorganisms insensitive to the drug, especially yeast-like fungi.

When using the drug, systemic absorption of clindamycin is possible. During systemic use of clindamycin severe diarrhea and in some cases pseudomembranous colitis may develop. That is why in case of pronounced or prolonged diarrhea during Dalacin therapy the drug should be discontinued, diagnostic procedures should be performed and if necessary, appropriate treatment should be prescribed.

Dalacin in the form of vaginal suppositories and vaginal cream contains components that may reduce the strength of latex or rubber products (condoms, contraceptive vaginal diaphragms). Therefore, the use of such products during treatment with Dalacin in the form of vaginal suppositories and vaginal cream is not recommended.

Contraindications

Hypersensitivity to clindamycin, lincomycin or any component of Dalacin.

Side effects

The incidence of the following side effects is less than 10%.

In the genital system: irritation of the mucous membrane of the vulva and the vagina, vaginal pain, vaginal discharge, vaginal candidiasis, vulvovaginitis, trichomonas vaginitis, vaginal infections, menstrual disorders, uterine bleeding, abnormal labor, endometriosis.

Urinary system disorders: dysuria, urinary tract infections (including pyelonephritis), proteinuria.

Digestive system disorders: generalized abdominal pain, localized abdominal pain, abdominal cramps, abdominal distension, dyspepsia, nausea, vomiting, diarrhea, constipation, flatulence, bad breath, perversion of taste.

CNS side: dizziness, headache.

Dermatological reactions: rash, itching, maculopapular rash, erythema, candidiasis of the skin.

Allergic reactions: urticaria.

Endocrine system disorders: glucosuria, hyperthyroidism.

Actually: fungal infections, fever, flank pain, back pain, abdominal pain, generalized pain, bacterial infections, inflammatory edema, upper respiratory tract infections, nasal bleeding, abnormal results of microbiological tests.

Local reactions: itching and pain at the injection site.

Pregnancy use

Adequate and controlled studies on the use of the drug in the first trimester of pregnancy have not been conducted. The use of Dalacin in the first trimester of pregnancy is possible only if the estimated benefit exceeds the potential risk to the fetus.

The use of clindamycin preparations in the second and third trimesters of pregnancy in intravaginal dosage forms has not shown an increased incidence of fetal congenital abnormalities. If Dalacin is used in the second and third trimesters of pregnancy (although there have been no official studies on the use of suppositories in pregnancy), adverse effects on the fetus seem unlikely.

There are currently no data on the excretion of clindamycin with breast milk during intravaginal use of Dalacin. However, it has been found that when clindamycin is administered orally or parenterally, some amount is detected in breast milk.

Therefore, when deciding whether to prescribe Dalacin during lactation (breastfeeding), the expected benefit to the mother and the possible risk to the baby should be compared.

Similarities